{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:10:48Z","timestamp":1767838248781,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.leukres.2010.01.012","type":"journal-article","created":{"date-parts":[[2010,2,10]],"date-time":"2010-02-10T09:22:34Z","timestamp":1265793754000},"page":"1336-1339","source":"Crossref","is-referenced-by-count":16,"title":["Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib"],"prefix":"10.1016","volume":"34","author":[{"given":"Giovanni","family":"Carulli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Cannizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Ottaviano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cervetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Barat\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Marini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2010.01.012_bib1","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.18553\/jmcp.2007.13.s8-a.8","article-title":"Targeted chronic myeloid leukemia therapy: seeking a cure","volume":"13","author":"Fausel","year":"2007","journal-title":"J Manage Care Pharm"},{"key":"10.1016\/j.leukres.2010.01.012_bib2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdi127","article-title":"Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20\u201321 March 2004, under the auspices of ESMO","volume":"16","author":"Blay","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.leukres.2010.01.012_bib3","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Goldman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.01.012_bib4","first-page":"M11","article-title":"BCR-ABL inhibition as a modality of CML therapeutics","volume":"1551","author":"Buchdunger","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2010.01.012_bib5","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMe030009","article-title":"Imatinib mesylate\u2014the new gold standard for treatment of chronic myeloid leukemia","volume":"348","author":"Peggs","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2010.01.012_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"The Abl protein-tyrosine kinase inhibitor, STI571, inhibits in vitro signal transduction mediated by c-Kit and PDGF receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.leukres.2010.01.012_bib7","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.leukres.2008.03.008","article-title":"JAK-2V617F mutation in RARS-t: a target for Imatinib therapy?","volume":"32","author":"Cannizzo","year":"2008","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2010.01.012_bib8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2003-12-4266","article-title":"Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo","volume":"104","author":"Dietz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.01.012_bib9","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib mesylate inhibits T-cell receptor-mediated T-cell proliferation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.01.012_bib10","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","article-title":"Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections","volume":"108","author":"Mumprecht","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.01.012_bib11","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.exphem.2007.04.016","article-title":"Modulation of T-effector function by imatinib at the level of cytokine secretion","volume":"35","author":"Leder","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2010.01.012_bib12","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI28546.","article-title":"Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis","volume":"116","author":"Paniagua","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.leukres.2010.01.012_bib13","first-page":"762","article-title":"Chronic myeloid leukemia patients resistant to or intolerant of interferon \u03b1 and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia","volume":"88","author":"Steegmann","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.01.012_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.leukres.2007.02.013","article-title":"Reduction of immunoglobulin levels during imatinib therapy for chronic myeloid leukemia","volume":"32","author":"Cervetti","year":"2008","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2010.01.012_bib15","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3324\/haematol.12642","article-title":"Development of hypogammaglobulinemia in patients with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumors","volume":"93","author":"Santachiara","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.01.012_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.01.012_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.01.012_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/gcc.20433","article-title":"Proposal for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes","volume":"46","author":"Haferlach","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.leukres.2010.01.012_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2010.01.012_bib20","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/beha.2002.0192","article-title":"Minimal residual disease monitoring in multiple myeloma","volume":"15","author":"Davies","year":"2002","journal-title":"Best Pract Res Clin Hematol"},{"key":"10.1016\/j.leukres.2010.01.012_bib21","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ejca.2005.11.039","article-title":"Conventional diagnostics in multiple myeloma","volume":"42","author":"San Miguel","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.leukres.2010.01.012_bib22","first-page":"1234","article-title":"The phenotype of normal, reactive and malignant plasma cells. Identification of \u201cmany and multiple myelomas\u201d and new targets for myeloma therapy","volume":"91","author":"Bataille","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2010.01.012_bib23","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.4049\/jimmunol.165.12.6872","article-title":"The c-ABL tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19","volume":"106","author":"Zipfel","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.leukres.2010.01.012_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00277-008-0597-2","article-title":"Multiple myeloma developing after imanitib mesylate therapy for chronic myeloid leukemia","volume":"88","author":"Galanopoulos","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2010.01.012_bib25","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3748\/wjg.v13.i13.2011","article-title":"Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report","volume":"13","author":"Tzilves","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.leukres.2010.01.012_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1634\/theoncologist.10-6-457","article-title":"Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate","volume":"10","author":"Garipidou","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.leukres.2010.01.012_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.molmed.2005.07.007","article-title":"Imatinib: the narrow line between immune tolerance and activation","volume":"11","author":"Mothy","year":"2005","journal-title":"Trends Mol Med"},{"issue":"October","key":"10.1016\/j.leukres.2010.01.012_bib28","article-title":"An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization","author":"Jourdan","year":"2009","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610000263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212610000263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T04:04:03Z","timestamp":1739851443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212610000263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0145212610000263"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2010.01.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}